we may add that Paul Maddon (ex lead Progenics) who helped developing PRO 140 retired when SHTF at their company and thus they had to sell everything reducing the pipeline around 2011-2012.
At the good times at Progenics, Maddon, Thompson and others did the PRO 140 research and showed great results.
Hence Thompson is - if I may say so, a bit 'pissed' that progress has been lagging in her view with this drug. Still following it.
But for sure, she also sees the potential.
So with good results, she may update her opinion paper this year or 2020. Something like that could finally break the ice, besides our frustrating financing situation (o8>
Catalyst: Financing + Profession Sentiment, while we may take good trial results for granted already.
Back to the cancer trial design: Can't be that they don't inject the dosage weekly, must be weekly. Otherwise they would harm patients intentionally.
News 
Market Data 
Discover 
AI
